X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

IP Explained: Four things to know about the Bayh-Dole Act

By Tom Wilbur  |    September 13, 2019
Thanks in large part to strong intellectual property protections – including policies that incentivize public and private investments in research and development (R&D) – the United States is the ...   Read More

IP Explained: Three forms of IP protections for medicines

By Tom Wilbur  |    August 27, 2019
Intellectual property (IP) protections for the biopharmaceutical sector provide incentives that help to promote the discovery and development of life-saving medicines for patients and foster a...   Read More

IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle

By Tom Wilbur  |    August 6, 2019
Patents are unique in that they are a form of IP protection established in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell...   Read More

IP Explained: Understanding biopharmaceutical innovation

By Andrew Powaleny  |    July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...   Read More

IP Explained: Why IP protections are important for biologic medicines

By Tom Wilbur  |    July 18, 2019
Biologics are cutting-edge therapies that treat or cure some of the most challenging and costly diseases. These medicines are created from living organisms through highly complex manufacturing...   Read More

IP Explained: What is Section 101 and why reforms are needed

By Tom Wilbur  |    June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...   Read More

IP Explained: How Hatch-Waxman successfully balances affordability and innovation

By Tom Wilbur  |    May 22, 2019
For three decades, The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, has fostered innovation, spurred competition and helped the United...   Read More

IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry

By Tom Wilbur  |    May 2, 2019
Strong patent protections are fundamental to the creation of new treatments and cures that extend and improve patients’ lives. In recent years, critics of the biopharmaceutical industry have...   Read More

IP Explained: What they are saying on the importance of strong intellectual property protections

By Tom Wilbur  |    April 24, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections to maintain its role as the global leader in biopharmaceutical innovation. Strong and...   Read More

IP Explained: Why patents are so critical to biopharmaceutical innovation

By Tom Wilbur  |    April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates